Trials / Completed
CompletedNCT00281515
Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer
An Open-label, Multicenter, Randomized Phase II Study to Compare the Effects of Paclitaxel/Carboplatin and Lonafarnib to Those of Paclitaxel/Carboplatin for First-line Treatment of Patients With Epithelial Ovarian Cancer FIGO Stages IIB-IV
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 105 (actual)
- Sponsor
- AGO Study Group · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the effects of Paclitaxel/Carboplatin and Lonafarnib to those of Paclitaxel/Carboplatin in primary treatment of patients with epithelial ovarian cancer.
Detailed description
Today the standard therapy for patients with advanced ovarian carcinoma is paclitaxel and carboplatin. Lonafarnib is a farnesyl transferase inhibitor (FTI) that is active against a broad spectrum of tumor cell lines in vitro and tumor xenografts in nude mice. Lonafarnib has single-agent antitumor activity as well as enhanced activity in combination with taxanes in a number of tumor cell lines and in vivo models.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lonafarnib | 100mg/twice a day during chemotherapie,in maintenance phase 200 mg twice a day |
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2011-12-01
- Completion
- 2011-12-01
- First posted
- 2006-01-25
- Last updated
- 2012-06-29
Locations
23 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00281515. Inclusion in this directory is not an endorsement.